Google Pixel 10A; FDA Reverses-Will Review Moderna mRNA Flu Vaccine; Google Announces Dates for I/O; Tesla Avoids Suspension in California Over Full Self Driving Claim

Google has dropped the Pixel 10A, their latest budget…or at least mid-priced phone. At $499, the price is still right, but theverge.com reports that it is really only slightly better than the 9A it replaces. The handset still has the same Tensor G4 chip as last year’s model, and just 8 gigs or RAM…which means it won’t have the horsepower to run the latest AI features that are available on the Pixel 10 series. No Magic Cue or Pixel Screenshots. If you are skeptical or just don’t like AI, you really won’t care. One new feature you might well care about is that the phone has SOS satellite communications…so if you are somewhere out of cell range and get into trouble, you can hold that phone up and call for help using the satellite connection. An example was given in an article of being chased by a bear in the woods. Note: any bear can outrun you. If you don’t need all the AI whistles and bells, the 10A is worth a look at under $500.

The FDA has reversed its stunning refusal to review Moderna’s mRNA flu vaccine. According to arstechnica.com, the reversal was made by political appointee Vinay Prasad, the Trump administration’s top vaccine regulator, who overruled a team of agency scientists and a top career official in rejecting Moderna’s application. Prasad’s ostensible reason for initially refusing to review the application was based not on Moderna’s vaccine, mRNA-1010, but on the established flu vaccine Moderna used for comparison in its Phase 3 trial. Moderna used licensed standard-dose influenza vaccines, including Fluarix, made by GlaxoSmithKline, in the trial, which involved nearly 41,000 adults aged 50 and older. In a letter to Moderna dated February 3, Prasad said this choice “does not reflect the best-available standard of care,” and therefore the trial was not “adequate and well-controlled.” Moderna acknowledged that FDA scientists had previously suggested that the company use a recommended high-dose flu vaccine in trial participants 65 and older. But the agency ultimately signed off on the trial design with the uniform standard dose, calling it “acceptable.” No guarantee that the FDA will approve the vaccine, but at least they are going to review it.

Google has announced the dates for I/O 2026. Theverge.com reports that that it will be May 19th and 20th. In a news release Google says it will share the “latest AI breakthroughs and updates in products across the company, from Gemini to Android and more” during the event, which will take place in-person in Mountain View, California’s Shoreline Amphitheatre, and online.

Tesla has agreed to change language describing their glorified cruise control, and stop using the word ‘Autopilot.’ Techcrunch.com notes that Tesla has stopped using ‘Full Self-Driving Capability.’ Now, they will say Full Self-Driving (Supervised), which is actually pretty accurate. The Autopilot term was contested by the state, and in December, an administrative law judge agreed with the DMV’s request to suspend Tesla’s sales and manufacturing licenses in California for 30 days. That got Tesla’s attention. The state DMV said Tesla now had 60 days to comply. The company agreed, and has dropped the ‘Autopilot’ term in marketing its cars in California. 

I’m Clark Reid and you’re ‘Technified’ for now.